Daniel L.
- Country
- Sweden
- Department
- FoUU Psychiatry Lund. Barav 1. SE 222 40 Lund.
Research Overview
- Long-term efficacy and tolerability of add-on pramipexole for anhedonic depression – an open label follow-up study
- Phase II Open-label Study of Adjunctive Ketamine Hydrochloride Prolonged-Release Tablets During Antidepressant Initiation in Patients with Major Depressive Disorder
- Evaluation of OSU6162 Hydrochloride as an Adjunct to SSRI/SNRI Therapy in Treatment-Resistant Major Depressive Disorder: A Double-Blind, Placebo-Controlled Study
Data & Insights
Has run more than one trial at 1 of 5 partner sites.
Specializations
Depression Treatment Innovation
The investigator specializes in the treatment of treatment-resistant depression, with particular focus on developing novel therapeutic approaches using adjunctive medications.
- Anhedonic Depression Management
- SSRI/SNRI-Resistant Depression
- Combination Therapy Approaches
Primary research interests include evaluating dopaminergic agents and novel compounds for enhancing antidepressant efficacy.
Therapeutic Strategies
Focused on investigating augmentation strategies in depression treatment, particularly examining the role of add-on therapies to standard antidepressant treatments.
- Long-term Treatment Outcomes
- Medication Tolerability
- Therapeutic Optimization
Expertise in evaluating novel pharmacological compounds for treatment-resistant cases.
Specialized Treatment Areas
Concentrates on addressing specific symptom domains in major depressive disorder, with particular attention to anhedonia treatment.
- Symptom-Specific Interventions
- Treatment Resistance
- Clinical Safety Assessment
Emphasis on developing targeted therapeutic approaches for treatment-refractory symptoms.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.